

**Investor Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
240-631-3280  
BurrowsR@ebsi.com

**Media Contact:**

Tracey Schmitt Lintott  
Vice President, Global Public Affairs  
and Corporate Responsibility  
240-631-3394  
SchmittT@ebsi.com

**EMERGENT BIOSOLUTIONS TO RELEASE FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS AND CONDUCT A CONFERENCE CALL ON FEBRUARY 25, 2016**

**GAITHERSBURG, MD, February 11, 2016**—Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 25, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2015, recent business developments, financial outlook for full year 2016, and revenue guidance for the first quarter of 2016.

This conference call can be accessed live by telephone or through Emergent’s website:

**Live Teleconference Information:**

Dial in number: **(855) 766-6521**  
*International dial in: (262) 912-6157*  
Passcode: **46021005**

**Live Webcast Information:**

Visit [emergentbiosolutions.com](http://emergentbiosolutions.com)  
and select the “[Investors](#)” section

*Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: [edge.media-server.com/m/p/9j5eeynk](http://edge.media-server.com/m/p/9j5eeynk).*

A replay of the call can be accessed on Emergent’s website [emergentbiosolutions.com](http://emergentbiosolutions.com) under “[Investors](#).”

**About Emergent BioSolutions Inc.**

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at [emergentbiosolutions.com](http://emergentbiosolutions.com).

Follow us on twitter: [@emergentbiosolu](https://twitter.com/emergentbiosolu).

###